Chronic kidney disease in type 2 diabetes mellitus patients: Comparison of KDIGO and KDOQI guidelines

Peer review under responsibility of Alexandria University Faculty of Medicine.

Available online 1 August 2018

Figures & data

Fig. 1 eGFR classification using KDIGO criteria.

Fig. 2 eGFR classification using KDOQI criteria.

Fig. 3 Degree of agreement between KDIGO and KDOQI definitions in diagnosing chronic kidney disease.

Table 1 Prevalence of CKD among participants.

CKD staging	KDIGO	KDOQI
G1	20 (9.9)	24 (11.9)
G2	54 (26.7)	55 (27.2)
G3a	43 (21.3)	35 (17.3)
G3b	10 (5.0)	3 (1.5)
G4	0 (0.0)	0 (0.0)
G5	1 (0.5)	1 (0.5)
Total CKD, n (%)
(Stages 1–5)	128 (63.4)	118 (58.4)

KDIGO: Kidney disease improving global outcome; KDOQI: Kidney disease outcome quality initiative.

Table 2 Prevalence of albuminuria, estimated glomerular filtration rate (eGFR).

	Total	Male	Female	P-value
	(n = 202)	(n = 43)	(n = 159)
Albuminuria				0.789
Yes	95 (47.0)	21 (22.1)	74 (77.9)
No	107 (53.0)	22 (20.6)	85 (79.4)
Albuminuria grades				0.812
Negative	107 (53.0)	22 (20.6)	85 (79.4)
Trace	51 (25.2)	13 (25.5)	38 (74.5)
1+	30 (14.9)	5 (16.7)	25 (83.3)
2+	14 (6.9)	3 (21.4)	11 (78.6)
Albuminuria				0.669
<30 mg/dl	51 (25.4)	13 (30.2)	38 (24.1)
30–299 mg/dl	44 (21.9)	8 (18.6)	36 (22.8)
KDIGO eGFR, n (%)				0.845
≥60	148 (73.3)	31 (20.9)	117 (79.1)
<60	54 (26.7)	12 (22.2)	42 (77.8)
KDOQI eGFR, n (%)				0.571
≥60	163 (80.7)	36 (22.1)	127 (77.9)
<60	39 (19.3)	7 (17.9)	32 (82.1)

Table 3 Prevalence of CKD among diabetic patients based on Albuminuria staging using KDIGO criteria.

	Albuminuria
CKD staging	A1	A2	Total (n = 202)
	<30	30–299
G1: ≥90	9 (4.5)	11 (5.4)	20 (9.9)
G2: 60–89	32 (15.8)	22 (10.9)	54 (26.7)
G3a: 45–59	10 (5.0)	8 (4.0)	18 (8.9)
G3b: 30–44	0 (0.0)	2 (1.0)	2 (1.0)
G4: 15–29	0 (0.0)	0 (0.0)	0 (0.0)
G5: <15	0 (0.0)	1 (0.5)	1 (0.5)

Table 4 Prevalence of CKD among diabetic patients based on Albuminuria staging using KDOQI criteria.

	Albuminuria
CKD staging	A1	A2	Total (n = 202)
	< 30	30–299
G1: ≥90	11 (5.4)	13 (6.4)	24 (11.9)
G2: 60–89	33 (16.3)	22 (10.9)	55 (37.2)
G3a: 45–59	7 (3.5)	7 (3.5)	14 (6.9)
G3b: 30–44	0 (0.0)	1 (0.5)	1 (0.5)
G4: 15–29	0 (0.0)	0 (0.0)	0 (0.0)
G5: <15	0 (0.0)	1 (0.5)	1 (0.5)

Table 5 Demographic characterizations of diabetic patients as determinants of CKD.

	KDIGO			KDOQI
	(n = 128)	OR (95% CI)	P-value	(n = 118)	OR (95% CI)	P-value
Gender
Male	29 (22.7)	1		27 (22.9)	1
Female	99 (77.3)	0.80 (0.39–1.63)	0.532	91 (77.1)	0.79 (0.40–1.59)	0.512
Age group n (%)
30–39	3 (2.3)	1		3 (2.5)	1
40–49	18 (14.1)	1.85 (0.35–9.70)	0.469	18 (15.3)	1.85 (0.35–9.69)	0.469
50–59	29 (22.7)	1.29 (0.27–6.27)	0.753	28 (23.7)	1.20 (0.25–5.86)	0.818
60–69	47 (36.7)	2.61 (0.54–12.62)	0.233	43 (36.4)	2.05 (0.43–9.85)	0.371
70–79	23 (18.0)	10.22 (1.50–69.76)	0.018	20 (16.9)	4.44 (0.77–25.65)	0.095
≥ 80	8 (6.2)			6 (5.1)	4.00 (0.45–35.79)	0.215
BMI n (%)
Underweight	4 (3.1)	0.74 (0.15–3.65)	0.712	3 (2.5)	0.52 (0.11–2.56)	0.424
Normal	36 (28.1)	1		33 (28.0)	1
Overweight	34 (26.6)	0.79 (0.37–1.68)	0.535	31 (26.3)	0.80 (0.38–1.68)	0.556
Obese	54 (42.2)	1.11 (0.54–2.27)	0.773	51 (43.2)	1.19 (0.59–2.38)	0.634
Duration of condition
<5 yrs	52 (40.6)	1		49 (41.5)	1
5–10 yrs	54 (42.2)	0.78 (0.42–1.46)	0.435	50 (42.4)	0.77 (0.41–1.42)	0.395
11–15 yrs	8 (6.2)	0.52 (0.18–1.54)	0.236	7 (5.9)	0.48 (0.16–1.41)	0.181
16–20 yrs	8 (6.2)	2.08 (0.41–10.48)	0.376	7 (5.9)	1.43 (0.34–5.95)	0.624
>20 yrs	6 (4.7)	3.12 (0.36–27.21)	0.304	5 (4.2)	1.53 (0.28–8.39)	0.624
Anti-diabetic drug
Yes	127 (99.2)	3.53 (0.31–39.59)	0.307	117 (99.2)	2.85 (0.26–32.00)	0.395
No	1 (0.8)	1		1 (0.8)	1
Medication
None	1 (0.8)	1		1 (0.8)	1
Oral OHA	122 (95.3)	3.70 (0.33–41.54)	0.289	112 (94.9)	2.95 (0.26–33.08)	0.381
Insulin	4 (3.1)	1.33 (0.09–20.11)	0.835	4 (3.4)	1.33 (0.09–20.11)	0.835
Both	1 (0.8)			1 (0.8)
Years on medication
<5 yrs	57 (44.5)	4.22 (0.37–48.62)	0.248	54 (45.8)	3.60 (0.31–41.37)	0.304
5–10 yrs	50 (39.1)	2.70 (0.24–30.94)	0.424	46 (39.0)	2.24 (0.20–25.67)	0.516
11–15 yrs	8 (6.2)	2.67 (0.19–36.76)	0.464	7 (5.9)	2.00 (0.15–27.45)	0.604
16–20 yrs	7 (5.5)	14.00 (0.58–33.88)	0.105	6 (5.1)	6.00 (0.34–10.74)	0.224
>20 yrs	5 (3.9)	10.00 (0.40–25.04)	0.161	4 (3.4)	4.00 (0.21–75.66)	0.355